<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/59615">
      <dc:title>Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer</dc:title>
      <dc:creator>Martín Blázquez, Ariadna</dc:creator>
      <dc:creator>Díaz, Caridad</dc:creator>
      <dc:creator>González Flores, Encarnación</dc:creator>
      <dc:creator>Franco Rivas, Daniel</dc:creator>
      <dc:creator>Jiménez Luna, Cristina</dc:creator>
      <dc:creator>Melguizo Alonso, Consolación</dc:creator>
      <dc:creator>Prados Salazar, José Carlos</dc:creator>
      <dc:creator>Genilloud Rodríguez, Olga</dc:creator>
      <dc:creator>Vicente, Francisca</dc:creator>
      <dc:creator>Caba Pérez, Octavio</dc:creator>
      <dc:creator>Pérez del Palacio, José</dc:creator>
      <dc:description>Colorectal cancer is one of the main causes of cancer death worldwide, and novel biomarkers are&#xd;
urgently needed for its early diagnosis and treatment. The utilization of metabolomics to identify&#xd;
and quantify metabolites in body fluids may allow the detection of changes in their concentrations&#xd;
that could serve as diagnostic markers for colorectal cancer and may also represent new therapeutic&#xd;
targets. Metabolomics generates a pathophysiological ‘fingerprint’ that is unique to each individual.&#xd;
The purpose of our study was to identify a differential metabolomic signature for metastatic colorectal&#xd;
cancer. Serum samples from 60 healthy controls and 65 patients with metastatic colorectal cancer were&#xd;
studied by liquid chromatography coupled to high-resolution mass spectrometry in an untargeted&#xd;
metabolomic approach. Multivariate analysis revealed a separation between patients with metastatic&#xd;
colorectal cancer and healthy controls, who significantly differed in serum concentrations of one&#xd;
endocannabinoid, two glycerophospholipids, and two sphingolipids. These findings demonstrate that&#xd;
metabolomics using liquid-chromatography coupled to high-resolution mass spectrometry offers a&#xd;
potent diagnostic tool for metastatic colorectal cancer.</dc:description>
      <dc:date>2020-02-12T12:53:44Z</dc:date>
      <dc:date>2020-02-12T12:53:44Z</dc:date>
      <dc:date>2019</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Martín-Blázquez, A., Díaz, C., González-Flores, E., Franco-Rivas, D., Jiménez-Luna, C., Melguizo, C., ... &amp; del Palacio, J. P. (2019). Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Scientific Reports, 9(1), 1-9.</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/59615</dc:identifier>
      <dc:identifier>10.1038/s41598-019-55952-8</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>Springer Nature</dc:publisher>
   </ow:Publication>
</rdf:RDF>